Immutep (IMMP) Income from Discontinued Operations (2016 - 2017)
Immutep (IMMP) posted Income from Discontinued Operations of 31287.16 for Q2 2017, down 71.3% on a QoQ basis from 108998.04 in Q1 2017, and down 87.84% year-over-year from 257345.01 in Q2 2016.
Immutep (IMMP) Income from Discontinued Operations (2016 - 2017) Analysis & Trends
Immutep's Income from Discontinued Operations history runs 2 years deep, the most recent figure standing at 31287.16 for Q2 2017.
- Quarterly Income from Discontinued Operations fell 87.84% year-over-year to 31287.16 in Q2 2017, while the trailing twelve-month figure through Jun 2017 was 811609.62 (changed N/A YoY) and the FY2017 annual result came in at 553932.73, down 37.19% from the prior year.
- Income from Discontinued Operations was 31287.16 for Q2 2017 at Immutep, down from 108998.04 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 413979.41 in Q4 2016 and bottomed at 31287.16 in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | - |
| 10 | Immutep | 567.77 Mn | 567.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 31,287.16 |
| Mar 31, 2017 | 108,998.04 |
| Dec 31, 2016 | 413,979.41 |
| Jun 30, 2016 | 257,345.01 |
| Mar 31, 2016 | 198,102.93 |